Does Preoperative Antiviral Treatment for Hepatitis C Decrease Risk of Complications After Total Hip Arthroplasty? A
Austin J Ross1, Bailey J Ross1, Olivia C Lee2
1Department of Orthopaedic Surgery, Tulane University School of Medicine, New Orleans, Louisiana.
Insights
Hepatitis C virus (HCV) increases complications after hip replacement. Preoperative antiviral treatment significantly lowers these risks, especially for readmission and joint infection.
Area of Science:
- Orthopedic surgery
- Infectious diseases
- Hepatology
Background:
- Hepatitis C virus (HCV) infection is linked to higher complication rates after elective arthroplasty.
- Understanding these risks is crucial for patient management and surgical outcomes.
Purpose of the Study:
- To assess the impact of HCV on complications following total hip arthroplasty (THA).
- To evaluate the effect of pre-THA antiviral treatment in HCV patients on postoperative complications.
Main Methods:
- Retrospective matched cohort study using an administrative claims database.
- Matched 6,883 HCV patients with 20,694 controls; 920 treated HCV patients with 3,820 untreated HCV patients.
- Compared 90-day medical and 2-year joint complication rates using multivariable logistic regression.
Main Results:
- HCV patients had significantly higher rates of 90-day medical complications versus controls.
- At 2 years, HCV patients showed increased risk for revision THA, dislocation, mechanical complications, periprostastic fracture, and prosthetic joint infection (PJI).
- Pre-THA antiviral treatment in HCV patients resulted in comparable joint complication risks to controls and lower readmission/PJI rates versus untreated HCV patients.
Conclusions:
- HCV significantly elevates medical and joint complication risks post-THA.
- Preoperative antiviral therapy in HCV patients effectively mitigates these risks, improving outcomes.
Background:
Hepatitis C virus (HCV) is associated with increased complication risk after elective arthroplasty. The purpose of this study is to examine the impact of HCV and prearthroplasty antiviral treatment on complications following total hip arthroplasty (THA).
Methods:
A retrospective matched cohort study was conducted using an administrative claims database. In total, 6,883 HCV patients were matched 1:3 with 20,694 noninfected controls, and 920 HCV patients with antiviral treatment before THA (treated HCV) were matched 1:4 with 3,820 HCV patients without treatment (untreated HCV). Rates of 90-day medical complications and joint complications within 2 years postoperatively were compared with multivariable logistic regression.
Results:
HCV patients exhibited significantly increased rates of medical complications within 90 days compared to noninfected controls (all P < .01). At 2 years postoperatively, HCV patients also exhibited significantly higher risk of revision THA (odds ratio [OR] 1.81), dislocation (OR 2.06), mechanical complications (OR 1.40), periprosthetic fracture (OR 1.76), and prosthetic joint infection (PJI) (OR 1.79). However, treated HCV patients exhibited statistically comparable risk of all joint complications at 2 years postoperatively relative to controls (all P > .05). Compared to untreated HCV patients, treated HCV patients exhibited significantly lower risk of inpatient readmission within 90 days (OR 0.58) and PJI at 2 years postoperatively (OR 0.62).
Conclusion:
HCV patients exhibit significantly increased risk of medical and joint complications following THA relative to controls, though prearthroplasty antiviral treatment mitigates complication risk. Treated HCV patients exhibited significantly lower risk of inpatient readmission and PJI compared to untreated HCV patients.
Level Of Evidence:
Level III.
Related Concept Videos
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Retrovirus Life Cycles
Venous Thrombosis III: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management


